{
    "organizations": [],
    "uuid": "3a9ff2e0e11816f2bfec9da70ac9fe92dc429248",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-vicore-pharma-receives-approval-to/brief-vicore-pharma-receives-approval-to-start-phase-iia-study-idUSFWN1RV0CF",
    "ord_in_thread": 0,
    "title": "BRIEF-Vicore Pharma Receives Approval To Start Phase IIa Study",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 18 (Reuters) - VICORE PHARMA HOLDING AB:\n* VICORE PHARMA RECEIVES APPROVAL TO START PHASE IIA STUDY IN IPF\n* APPROVAL FROM BRITISH MEDICINES AGENCY MHRA AND ETHICS COMMITTEE FOR LONDON AND SURREY FOR PHASE IIA STUDY ON IPF Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-04-18T17:20:00.000+03:00",
    "crawled": "2018-04-19T14:47:19.103+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "vicore",
        "pharma",
        "holding",
        "ab",
        "vicore",
        "pharma",
        "receives",
        "approval",
        "start",
        "phase",
        "iia",
        "study",
        "ipf",
        "approval",
        "british",
        "medicine",
        "agency",
        "mhra",
        "ethic",
        "committee",
        "london",
        "surrey",
        "phase",
        "iia",
        "study",
        "ipf",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}